Tremelimumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Tremelimumab |
| DrugBank ID | DB11771 |
| Brand Names (EU) | Imjudo |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.49% |
Approved Indication (EMA)
Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | diabetic cataract | 98.49% | DL |
| 2 | mature cataract | 98.41% | DL |
| 3 | tetanic cataract | 98.41% | DL |
| 4 | immature cataract | 98.41% | DL |
| 5 | diabetes mellitus type 2 associated cataract | 98.41% | DL |
| 6 | craniostenosis cataract | 98.41% | DL |
| 7 | cortical cataract | 98.39% | DL |
| 8 | nuclear senile cataract | 98.39% | DL |
| 9 | senile cataract | 98.33% | DL |
| 10 | diabetic retinopathy | 98.19% | DL |
| 11 | antithrombin deficiency type 2 | 97.94% | DL |
| 12 | severe nonproliferative diabetic retinopathy | 97.93% | DL |
| 13 | factor 5 excess with spontaneous thrombosis | 97.89% | DL |
| 14 | heparin cofactor 2 deficiency | 97.83% | DL |
| 15 | thrombophilia | 97.56% | DL |
| 16 | diffuse gastric adenocarcinoma | 95.40% | DL |
| 17 | hemorrhagic disease of newborn | 95.17% | DL |
| 18 | gastric adenocarcinoma and proximal polyposis of the stomach | 94.71% | DL |
| 19 | gastric carcinoma | 94.71% | DL |
| 20 | gastric tubular adenocarcinoma | 94.59% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.